Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination-Reference-Cited by-同舟云学术

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

Published:2024-05 Issue:5 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Younes Salma¹²,Nicolai Eleonora³,Pieri Massimo³⁴,Bernardini Sergio³⁴,Daas Hanin I.⁵,Al‐Sadeq Duaa W.⁶,Younes Nadin¹²,Shurrab Farah M.²,Nizamuddin Parveen B.¹,Humaira Fathima¹,Al‐Dewik Nader⁷⁸,Yassine Hadi M.¹²,Abu‐Raddad Laith J.⁹¹⁰¹¹^ORCID,Ismail Ahmed¹²,Nasrallah Gheyath K.¹²^ORCID

Affiliation:

1. Biomedical Sciences Department, College of Health Sciences Qatar University Doha Qatar

2. Biomedical Research Center Qatar University Doha Qatar

3. Department of Experimental Medicine University of Rome Tor Vergata Rome Italy

4. Clinical Biochemistry Tor Vergata University Hospital Rome Italy

5. College of Dental Medicine, QU Health Qatar University Doha Qatar

6. Department of Basic Medical Sciences, College of Medicine, QU Health Qatar University Doha Qatar

7. Department of Research and Translational and Precision Medicine Research Lab, Women's Wellness and Research Center Hamad Medical Corporation Doha Qatar

8. Genomics and Precision Medicine (GPM), College of Health & Life Science (CHLS) Hamad Bin Khalifa University (HBKU) Doha Qatar

9. Infectious Disease Epidemiology Group, Weill Cornell Medicine–Qatar Cornell University, Qatar Foundation – Education City Doha Qatar

10. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar Cornell University, Qatar Foundation – Education City Doha Qatar

11. Department of Healthcare Policy and Research, Weill Cornell Medicine Cornell University New York USA

12. Laboratory Section, Medical Commission Department Ministry of Public Health Doha Qatar

Abstract

ABSTRACTBackgroundPriming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lacking. In this study, we aimed to conduct a comparative assessment of the immunogenicity between homologous primary vaccination regimens and heterologous prime‐boost vaccination using BNT162b2 or mRNA‐1273.MethodsWe matched vaccinated naïve (VN) individuals (n = 673) with partial vaccination (n = 64), primary vaccination (n = 590), and primary series plus mRNA vaccine heterologous booster (n = 19) with unvaccinated naturally infected (NI) individuals with a documented primary SARS‐CoV‐2 infection (n = 206). We measured the levels of neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti‐S‐RBD IgG, and anti‐S1 IgA titers.ResultsHomologous primary vaccination with ChAdOx1 not only showed less potent NTAb, TAb, anti‐S‐RBD IgG, and anti‐S1 IgA immune responses compared to primary BNT162b2 or mRNA‐1273 vaccination regimens (p < 0.05) but also showed ~3‐fold less anti‐S1 IgA response compared to infection‐induced immunity (p < 0.001). Nevertheless, a heterologous booster led to an increase of ~12 times in the immune response when compared to two consecutive homologous ChAdOx1 immunizations. Furthermore, correlation analyses revealed that both anti‐S‐RBD IgG and anti‐S1 IgA significantly contributed to virus neutralization among NI individuals, particularly in symptomatic and pauci‐symptomatic individuals, whereas among VN individuals, anti‐S‐RBD IgG was the main contributor to virus neutralization.ConclusionThe results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.

Funder

World Health Organization

Qatar University

Qatar National Research Fund

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13290

Reference43 articles.

1. WHO “WHO Coronavirus (COVID‐19) Dashboard [Internet] ”https://covid19.who.int/.

2. “Total COVID‐19 Vaccine Doses Administered—Our World in Data ” accessed 16 Mar 2023 https://ourworldindata.org/grapher/cumulative‐covid‐vaccinations?country=~OWID_WRL.

3. Centers for Disease Control and Prevention “Understanding mRNA COVID‐19 Vaccines ” Centers for Disease Control and Prevention (2021).https://www.cdc.gov/coronavirus/2019‐ncov/vaccines/different‐vaccines/mrna.html.

4. Waning Immunity after the BNT162b2 Vaccine in Israel

5. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar